JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Aandelen Lijst・Kura Oncology Inc

Kura Oncology Inc

Gesloten

SectorGezondheidszorg

8.79 -1.01

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.73

Max

8.85

Belangrijke statistieken
By Trading Economics
Inkomsten	-6.9M -81M
Verkoop	-3.4M 17M
Winstmarge	-467.23
Werknemers	260
EBITDA	-12M -86M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+204.11% upside

Dividenden
By Dow Jones
Volgende Winsten	12 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	66M 821M
Vorige openingsprijs	9.8
Vorige sluitingsprijs	8.79

Nieuwssentiment

By Acuity

50%

180 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

5.575 / 6.6 Steun & Weerstand

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 mei 2026, 23:43 UTC

Belangrijke Nieuwsgebeurtenissen

New Zealand's Unemployment Rate Falls in 1Q

5 mei 2026, 23:20 UTC

Populaire aandelen

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 mei 2026, 21:48 UTC

Winsten

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 mei 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 mei 2026, 00:00 UTC

Marktinformatie

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 mei 2026, 23:39 UTC

Marktinformatie

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 mei 2026, 22:26 UTC

Marktinformatie

AMD Data-Center Business Continues to Surge -- Market Talk

5 mei 2026, 22:20 UTC

Marktinformatie

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 mei 2026, 22:08 UTC

Winsten

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 mei 2026, 22:07 UTC

Winsten

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:48 UTC

Winsten

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 mei 2026, 21:48 UTC

Winsten

Pan American Silver 1Q Rev $1.2B >PAAS

5 mei 2026, 21:42 UTC

Winsten

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mei 2026, 21:38 UTC

Winsten

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:30 UTC

Winsten

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mei 2026, 21:29 UTC

Winsten

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:26 UTC

Winsten

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 mei 2026, 21:25 UTC

Winsten

Alcon Inc. 1Q EPS 39c >ALC.EB

5 mei 2026, 21:25 UTC

Winsten

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 mei 2026, 21:24 UTC

Winsten

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:18 UTC

Winsten

Mistras Backs 2026 Rev $730M-$750M >MG

5 mei 2026, 21:17 UTC

Winsten

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 mei 2026, 21:15 UTC

Winsten

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 mei 2026, 21:12 UTC

Winsten

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 mei 2026, 21:11 UTC

Winsten

SSR Mining 1Q Rev $581.8M >SSRM

5 mei 2026, 21:10 UTC

Winsten

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 mei 2026, 21:10 UTC

Winsten

SSR Mining 1Q EPS $1.16 >SSRM

5 mei 2026, 21:08 UTC

Winsten

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mei 2026, 21:01 UTC

Winsten

Intact Financial 1Q EPS C$4.12 >IFC.T

5 mei 2026, 21:01 UTC

Populaire aandelen

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

204.11% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.13 USD 204.11%

Hoogste 40 USD

Laagste 15 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Kura Oncology Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.575 / 6.6Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

180 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.